Cargando…

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval

BACKGROUND: Several clinical studies have established the efficacy, safety, and tolerability of long-acting risperidone administered once every 2 weeks in patients with schizophrenia or schizoaffective disorder. This report evaluates preliminary efficacy, safety, tolerability, and pharmacokinetic da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gharabawi, Georges M, Gearhart, Natalie C, Lasser, Robert A, Mahmoud, Ramy A, Zhu, Young, Mannaert, Erik, Naessens, Ineke, Bossie, Cynthia A, Kujawa, Mary, Simpson, George M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1803785/ https://www.ncbi.nlm.nih.gov/pubmed/17261186 http://dx.doi.org/10.1186/1744-859X-6-3

Ejemplares similares

Evaluating movement disorders in pediatric patients receiving risperidone: a comparison of spontaneous reports and research criteria for TD
por: Pandina, Gahan J, et al.
Publicado: (2007)

Role of paliperidone extended-release in treatment of schizoaffective disorder
por: Canuso, Carla M, et al.
Publicado: (2010)

Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder
por: Bossie, Cynthia A., et al.
Publicado: (2017)

Report of three cases that received maintenance treatment with risperidone as a mood stabilizer
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2004)

Schizoaffective Disorder That Is Induced By Electrical Voltage That Is Treated with Risperidone
por: Fadhilah, Ihsan, et al.
Publicado: (2019)

Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study
por: Gianfrancesco, Frank D, et al.
Publicado: (2009)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders
por: Pinna, Federica, et al.
Publicado: (2015)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder
por: Fu, Dong-Jing, et al.
Publicado: (2016)

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2004)

A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting
por: Hsieh, Ming-Hong, et al.
Publicado: (2010)

Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study
por: Dhanda, Rahul, et al.
Publicado: (2019)

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium
por: Lambert, Tim, et al.
Publicado: (2011)

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
por: Alphs, Larry, et al.
Publicado: (2011)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
por: Turkoz, Ibrahim, et al.
Publicado: (2011)

A case report of schizoaffective disorder with ritualistic behaviors and catatonic stupor: successful treatment by risperidone and modified electroconvulsive therapy
por: Bai, Yuanhan, et al.
Publicado: (2018)

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations
por: Tchobaniouk, Lesia V, et al.
Publicado: (2019)

Efficacy and safety of once-monthly Risperidone ISM(®) in schizophrenic patients with an acute exacerbation
por: Correll, Christoph U., et al.
Publicado: (2020)

Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial
por: Gharabawi, Georges M, et al.
Publicado: (2006)

Maintenance electroconvulsive therapy for comorbid pharmacotherapy-refractory obsessive-compulsive and schizoaffective disorder
por: Hanisch, F, et al.
Publicado: (2009)

Carbamazepine and psychotherapy in the treatment of schizoaffective psychosis.
por: Cegalis, J. A., et al.
Publicado: (1985)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa, Jennifer Kern, et al.
Publicado: (2012)

Valproate-induced hypothyroidism in schizoaffective disorder
por: Facucho-Oliveira, J., et al.
Publicado: (2022)

SCHIZOAFFECTIVE DISORDER : CONSISTENCY OF DIAGNOSIS
por: Shrivastava, Amresh, et al.
Publicado: (1999)

Schizoaffective Disorder and Concurrent Rhabdomyolysis
por: Varkey, Thomas, et al.
Publicado: (2021)

To live with a Schizoaffective disorder
por: Arndtzén, Mats, et al.
Publicado: (2020)

The effect of risperidone and electroconvulsive therapy on corrected QT interval in electrocardiogram of psychiatric patients
por: Rezaei, Bahareh, et al.
Publicado: (2021)

Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial
por: Bossie, Cynthia A., et al.
Publicado: (2011)

QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy
por: Sala, Michela, et al.
Publicado: (2005)

Reducing the Diagnostic Heterogeneity of Schizoaffective Disorder
por: Seldin, Katherine, et al.
Publicado: (2017)

Cortical Alpha Activity in Schizoaffective Patients
por: Moeini, Mahdi, et al.
Publicado: (2017)

Schizoaffective disorder about 57 cases
por: Kammoun, I.
Publicado: (2021)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

A comparison of sexual desire in opiate-dependent men receiving methadone and buprenorphine maintenance treatment
por: Yee, Anne, et al.
Publicado: (2019)

Two cases of life‐threatening arrhythmia induced by risperidone: evaluation of risperidone and 9‐hydroxy‐risperidone concentrations
por: Ito, Asami, et al.
Publicado: (2017)

Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder
por: Mathalon, Daniel H., et al.
Publicado: (2010)

Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder
por: Archibald, Luke, et al.
Publicado: (2019)

Behavioural Changes in a Patient With Schizoaffective Disorder
por: Varughese, Anto
Publicado: (2022)

Schizoaffective disorder induced by substance abuse: a case report
por: García Carpintero, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k1ganicg8tnopu082p2etakgjv